In ovarian cancer cells, we showed that knockdown of BCL2 also reduces CSC-like populations, suggesting that the LARP1-mediated anti-CSC phenotype may also be mediated via BCL2 expression. The gene discussed is BCL2; the disease is ovarian carcinoma.